Expert Analysis

Focus on Investigational HCV Agents

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Focus on Investigational HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI
Ira M. Jacobson, MD
Stefan Zeuzem, MD

CME CREDIT INFORMATION

Release Date: 06/20/08

Expiration Date: 06/19/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data on the use of protease inhibitors in treatment-naive and nonresponder patients with genotype 1 chronic hepatitis C
Recount data on novel polymerase inhibitors for the treatment of genotype 1 chronic hepatitis C
Describe the importance of ribavirin in treating chronic hepatitis C and the role of ribavirin analogues
Describe new data on novel classes of drugs for the treatment of chronic hepatitis

Topics covered include:

Telaprevir-Based Combination Therapy in Treatment-Naive Patients With Genotype 1 HCV Infection
Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Previous Nonresponders to Peginterferon Plus Ribavirin
Boceprevir Plus Peginterferon alfa-2a/Ribavirin in Treatment-Naive, Genotype 1 Chronic Hepatitis C Patients
Boceprevir-Based Therapy in Genotype 1 HCV–Infected Previous Nonresponders
Pharmacokinetics and Safety of TMC435350
Polymerase Inhibitor R1626 in Treatment-Naive, Genotype 1 HCV-Infected Patients
Polymerase Inhibitor R7128 in Treatment-Naive Genotype 1 HCV-Infected Patients
Cyclophilin Inhibitor Debio-025 Plus Peginterferon alfa-2a in Treatment-Naive, Genotype 1 HCV Infection
Taribavirin vs Ribavirin in Treatment-Naive Genotype 1 HCV–Infected Patients
Nitazoxanide in Treatment-Naive Genotype 4 HCV–Infected Patients
Silibinin in Previous HCV Nonresponders
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.